Category Archives: Stem Cell Treatments

CLEARWATER, FL--(Marketwire -03/19/12)- Biostem U.S., Corporation (OTCQB: BOSM.PK - News) (Pinksheets: BOSM.PK - News) (Biostem, the Company), a fully reporting public company in the stem cell regenerative medicine sciences sector, announced today the addition of Perinatologist Sanford M. Lederman, MD to its Scientific and Medical Board of Advisors (SAMBA).

As Chairman of the Department of Obstetrics and Gynecology at New York Methodist Hospital in Brooklyn, Dr. Lederman is consistently recognized by New Yorker Magazine's list of "Top Doctors" in New York. A specialist in high-risk pregnancy issues, Dr. Lederman has authored a number of scientific papers and is a highly regarded public speaker. He adds a very important dimension to the Biostem Scientific and Medical Board of Advisors by bringing specialized knowledge regarding the potential use of stem cell applications for the health of women and children.

Biostem President Dwight Brunoehler said, "Dr. Lederman is one of the most highly respected Obstetric and Gynecological physicians in the country. Sandy and I have worked together very actively on stem cell projects for over 18 years, including setting up a cord blood stem cell national donation system where all expectant moms have a chance to donate their baby's cord blood to benefit others."

Dr. Lederman stated, "Biostem's expansion plans mesh well with my personal interest in developing and advancing the use of non-controversial stem cells to improve the health of women and children. I have a particular interest in increasing the use of cord blood stem cells for in-utero transplant procedures, where stem cells are used to cure a potential life threatening disease such as sickle cell or thalassemia and other selective genetic disorders in a baby before it is even born."

Prior to accepting his current position with New York Methodist Hospital, Dr. Lederman was Residency Program Director and Vice Chairman of the Department of Obstetrics and gynecology at Long Island College Hospital in Brooklyn. At various times, he has served as a partner at Brooklyn Women's Health Care, President at Genetics East and Clinical Associate Professor at the State University of New York. He has served on the medical advisory board of several companies. He previously was Medical Director of Women's Health USA and was a founding member of the Roger Freeman Perinatal Society.

A graduate of Hunter College in New York, he received his initial medical training at Universidad Autonoma de Guadalajara School of Medicine. His initial internship was at New York Medical College in the Bronx. During the course of his career, Dr. Lederman has served and studied in various capacities at Long Island College Hospital in the Bronx, North Shore University Hospital in New York, Kings County Medical Center in Brooklyn, Long Beach Memorial Medical Center in California and the University of California at Irvine.

About Biostem U.S., CorporationBiostem U.S., Corporation (OTCQB: BOSM.PK - News) is a fully reporting Nevada corporation with offices in Clearwater, Florida. Biostem is a technology licensing company with proprietary technology centered around providing hair re-growth using human stem cells. The company also intends to train and license selected physicians to provide Regenerative Cellular Therapy treatments to assist the body's natural approach to healing tendons, ligaments, joints and muscle injuries by using the patient's own stem cells. Biostem U.S. is seeking to expand its operations worldwide through licensing of its proprietary technology and acquisition of existing stem cell related facilities. The company's goal is to operate in the international biotech market, focusing on the rapidly growing regenerative medicine field, using ethically sourced adult stem cells to improve the quality and longevity of life for all mankind.

More information on Biostem U.S., Corporation can be obtained through http://www.biostemus.com, or by calling Kerry D'Amato, Marketing Director at 727-446-5000.

Read the original post:
Biostem U.S., Corporation Continues Building Its Scientific and Medical Board of Advisors With Appointment of Leading ...

14-10-2011 21:22 http://www.StemCellTreatment.org Stem cell treatment for Charge Syndrome was performed on Braulio and as you can see in this video he has improved drastically. He is now walking and his eyesight has improved. Charge syndrome is a serious condition and obviously difficult to live with. If you suffer or know someone who suffers from this condition please contact the American Stem Cell & Anti Aging Center at http

Continue reading here:
Stem Cell Treatment for Charge Syndrome - Video

02-08-2011 12:02 http://www.StemCellTreatment.org This is Galit's testimonial, a patient with Multiple Sclerosis. After a stem cell treatment for Multiple Sclerosis she shares her experience. She has gotten great results and is really happy with the stem cell therapy for multiple sclerosis she received as you can see by this video. If you or a loved one are suffering from multiple sclerosis please visit our website and give us a call!

Follow this link:
Stem Cell Treatment Multiple Sclerosis - Video

Interview with Dr. Zannos Grekos Grekos contests that his office has done ...

LEE COUNTY A week after Dr. Zannos Grekos was accused of performing a stem cell treatment on a patient who died, his attorney said another physician was treating the patient at the Bonita Springs practice.

And there was no stem cell treatment performed, only liposuction, said Richard Ozelie, the Boca Raton attorney representing Grekos.

Ozelie does not identify the other doctor but said in a statement Wednesday that the Lee County Sheriffs Office and the Lee County Medical Examiners Office both have that information.

The patient, identified by state authorities through the initials R.P., did have liposuction at the Regenocyte medical facility in Bonita Springs, Ozelie said in the statement. The Sheriffs Office later identified the man who died as Richard Poling , 77, of Newburgh, Ind.

The attorney issued the one-page statement because of concerns with the accuracy of media coverage after the state Department of Health suspended Grekos license March 7. The case has received some national media attention.

The next day, the Sheriffs Office launched a criminal investigation into Grekos practice, Regenocyte, 9500 Bonita Beach Road, Suite 310.

Sheriffs Office spokesman Lt. Larry King had no comment Wednesday and said the agencys investigation is continuing.

In the suspension order, the state health department said Grekos infused or directed that the patient have concentrated stem cells infused into his blood stream. The state order said the patient suffered cardiac arrest and died.

The emergency suspension was issued because Grekos violated a license restriction from February, 2011, not to do anything with autologous stem cell treatment or bone marrow aspirate, according to the state order.

Read the rest here:
Grekos' attorney: Another physician treated patient who died

03-10-2011 18:30 "I don't have any symptoms now." - Mrs. Morris discusses how stem cell therapy has improved her life; greatly increasing her range of motion and eliminating her pain. Mrs. Morris suffered with Rheumatoid Arthritis for over 30 years. She also explains how RA affected her before stem cell therapy including the laundry list of drugs shes taken over the years.

Continue reading here:
Stem Cell Treatment for Rheumatoid Arthritis - Darnell Morris - Video

(CNN) -

A Florida cardiologist could have his medical license revoked by state authorities who have accused him of performing illegal stem cell therapy on a patient who died during the procedure.

Florida's Department of Health ordered the emergency suspension of Zannos Grekos' medical license Wednesday, accusing the Bonita Springs doctor of violating an emergency order against using stem cell treatments in Florida and causing the death of an unidentified elderly patient. Grekos can appeal the order.

According to the license suspension order, Grekos performed a stem cell treatment this month on the patient, who was suffering from pulmonary hypertension and pulmonary fibrosis. Both diseases restrict blood flow to the heart.

"During said stem cell treatment, patient R.P. suffered a cardiac arrest and died," the suspension order said.

CNN first investigated Grekos' activities in 2009, when he said he was using stem cell therapy for a company called Regenocyte Therapeutic. His profile, listed on the company's website, describes Grekos as having "extensive experience in the field of stem cell therapy" and says he "was recently appointed to the Science Advisory Board of the United States' Repair Stem Cell Institute."

At the time of CNN's interview, Grekos said he extracted stem cells from patients and then sent the blood to Israel for laboratory processing. That processing, he said, resulted in "regenocytes," which he said would help heal crippling diseases, mostly associated with lung problems.

The president of the International Society of Stem Cell Research, Dr. Irving Weissman, told CNN at the time that "there is no such cell."

"There is nothing called a regenocyte," he said.

After CNN's initial report, Grekos said the name was "advertising" and was not intended to be scientific.

Read the original:
Patient dies during procedure

BONITA SPRINGS, FL -

The state Surgeon General has issued an emergency suspension of the license of Dr. Zannos Grekos for providing a stem cell treatment to a patient contrary to previous restrictions placed on his license. The patient died during the treatment.

According to the emergency suspension order, in February 2011 Dr. Grekos was ordered not to perform any stem cell treatments on patients.

On March 2, 2012, Grekos is accused of treating an elderly man with pulmonary hypertension and pulmonary fibrosis with stem cells.

The suspension order says Grekos harvested tissue from the patient's abdomen that commonly contains stem cells. That tissue was sent to a lab to have the stem cells concentrated.

Those concentrated stem cells were then injected into the patient's bloodstream, according to the order.

The patient died of cardiac arrest during the treatment.

Because the stem cell treatment violated previous restrictions on Grekos' license, the state requested the emergency suspension of his license.

One section of the emergency suspension order states, "Nothing short of the immediate suspension of Dr. Grekos' license to practice medicine would be sufficient to protect the public from the danger of harm presented by Dr. Grekos."

Since the news of his suspension, others who have been under Dr. Grekos' care have spoken up.

Original post:
Doctor's license suspended after patient's death

TYLER, TX (KLTV) -

A young Tyler mom is doing everything she can to get her young son to China for stem cell treatments -- and she needs your help.

Emily Roberts's son, Joel Hilton, was born with two conditions that have left him blind and unable to grow properly.

He was born with optic nerve hypoplasia and septo-optic dysplasia, conditions that affect his sight and his pituitary gland, which affect his growth and development.

"I just, I never -- I mean, everyone says this -- never thought it would be me. I mean, you don't expect me, especially at 18 years old, I did not expect to have a blind child. It's just, why me," Roberts said. "But it happened. And he's here."

Now, Roberts's hope is to raise enough money to take Joel to China. A hospital there has accepted Joel to receive five umbilical cord stem cell treatments, which Roberts hopes will help Joel regain some sight and help restore some of his pituitary gland.

"It's not a 100 percent thing. I don't want people thinking that he's going to go and come back and be able to see 20/20. No. Even if he can see a little bit or know when the light's on or the light's off, or if he can see shadows and movement, that would be a miracle, because right now he can't see anything," Roberts said.

Joel receives physical, occupational, and early childhood therapies twice a week, but Roberts is the first to admit that life with these conditions has been very different than she'd imagined.

"He's definitely not like a normal child. Normal kids run around and he sits right here with mommy," Roberts said. "I have to carry him everywhere, he can't walk. I mean, he can't talk, either. I just kind of have to know. I know him pretty well, though, because we're always together. He's like my little buddy."

And her hope for Joel is for improvement of any kind after the stem cell treatment.

See original here:
ETX mom hopes 'Joel's Journey for Sight' leads to China

SUNRISE, Fla., Feb. 28, 2012 (GLOBE NEWSWIRE) -- Bioheart, Inc. (BHRT.OB) announced that the company will conduct the ANGEL trial using adipose (fat) derived stem cell technology or LipiCell(TM) at the University of Miami Miller School of Medicine. Bioheart recently applied to the FDA to begin trials using adipose derived stem cells in patients with chronic ischemic cardiomyopathy.
"Dr. Joshua Hare and the University of Miami are world leaders in the field of stem cell research," said Mike Tomas, President and CEO of Bioheart. "We look forward to working with these acclaimed experts and bringing the LipiCell(TM) technology to patients in the U.S."
The clinical protocol of the ANGEL trial is designed to assess the safety and cardiovascular effects of intramyocardial implantation of autologous adipose derived stem cells (LipiCell(TM)) in patients with chronic ischemic cardiomyopathy. Joshua Hare, MD, Director of the Interdisciplinary Stem Cell Institute at the University of Miami Miller School of Medicine is the principle investigator of the clinical program.
The Interdisciplinary Stem Cell Institute was established to capitalize on pioneering work in the use of adult stem cells for the repair of malfunctioning human organs. The goal of the Institute is to find new treatments for heart disease, neurological disease, bone disease, diabetes, cancer, eye diseases and other chronic, debilitating, or incurable diseases. University of Miami scientists have led in the development of procedures to extract adult stem cells and have conducted ground breaking research in cell-based therapy for the diseased human heart.
About Bioheart, Inc.
Bioheart is committed to maintaining our leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Our goals are to cause damaged tissue to be regenerated, if possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.
Specific to biotechnology, we are focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Our leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit http://www.bioheartinc.com.
Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management's beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2010, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2011.

Link:
Bioheart Announces University of Miami as Clinical Site for ANGEL Trial of LipiCell(TM)

By Katherine Hobson

Stem-Cell Discovery: Research published in Nature Medicine suggests a way to take stem cells from a woman’s ovary and convert them into normal immature eggs that appear to be viable, the WSJ reports. While scientists say the development, if borne out, offers a potential research avenue for fertility treatments, they also caution that many obstacles remain.

Video-Game Study: Research published in Pediatrics suggests those “active” video games aren’t necessarily giving kids a lot more exercise than traditional games for sofa-sitters, Reuters reports. While the active games may slightly increase caloric burn for kids, they aren’t likely going to help them meet their daily recommended 60 minutes of activity, an outside researcher tells Reuters.

Medicaid Cuts: Washington state’s plan to cut off Medicaid payment for certain non-urgent medical services when delivered in an emergency room is riling providers, the WSJ reports. The move aims to reduce health-care costs by diverting patients to more appropriate venues for care, but physicians and hospitals say some of the procedures and tests are necessary to rule out emergency problems and that they will end up stuck with the bill, the paper says.

Trying to Treat Cachexia: Two experimental drugs to treat cachexia, the weight loss and muscle-wasting that often accompany cancer, are in late-stage clinical trials and if all goes well, could be available in two to three years, the Los Angeles Times reports. A researcher not affiliated with either of the companies developing the drugs says the hope is that the drugs will not only help cancer patients have more strength to fight their disease, but will also prolong life.

Image: iStockphoto

Read this article:
A.M. Vitals: Stem-Cell Experiment May Suggest Future Fertility Treatments